ABSTRACT
Randomized controlled trials of marine omega-3 fatty acid supplementation in relation to coronary heart disease (CHD) have inconsistent outcomes, yet public health messages are uniformly positive. Originally, fish were seen as a low saturated fat protein source, and later as a valuable source of omega-3 fatty acids. Early trials indicated that increased fish oil consumption prevented restenosis after coronary angioplasty. Later trials demonstrated that fish oils prolonged life post myocardial infarction (MI). Currently, the potential antiarrhythmic effects of fish derived omega-3 fatty acids are seen as the primary reason for cardiac benefits, as suggested by one trial with compliant subjects with implantable cardioverter defibrillators (ICDs), and sudden death reduction in a post MI trial. However, the earlier benefits of EPA and DHA on restenosis have only been confirmed in a subgroup in a recent meta-analysis. Newer data indicate that fish oils may increase CHD events in men with angina. Furthermore, in two of three trials in patients with ICDs and a history of ventricular arrhythmias, fish oils showed no significant benefit or even increased the risk of appropriate ICD discharge. Certain groups of individuals may benefit from long-chain omega-3 fatty acids while others, including men with angina and some individuals with a history of ventricular arrhythmia, may not. Due to significant heterogeneity in the response to fish oils, further studies are required before making widespread recommendations for all groups to increase consumption of fish and fish oil.
Subject(s)
Arrhythmias, Cardiac/prevention & control , Coronary Disease/diet therapy , Fish Oils/therapeutic use , Coronary Disease/complications , Coronary Disease/genetics , Coronary Restenosis/prevention & control , Dietary Supplements , Fish Oils/adverse effects , Fish Oils/pharmacology , Humans , Male , Meta-Analysis as Topic , Randomized Controlled Trials as Topic , Risk Factors , Secondary PreventionABSTRACT
BACKGROUND: A recent Cochrane meta-analysis did not confirm the benefits of fish and fish oil in the secondary prevention of cardiac death and myocardial infarction. We performed a meta-analysis of randomized controlled trials that examined the effect of fish-oil supplementation on ventricular fibrillation and ventricular tachycardia to determine the overall effect and to assess whether heterogeneity exists between trials. METHODS: We searched electronic databases (MEDLINE, EMBASE, The Cochrane Central Register of Controlled Trials, CINAHL) from inception to May 2007. We included randomized controlled trials of fish-oil supplementation on ventricular fibrillation or ventricular tachycardia in patients with implantable cardioverter defibrillators. The primary outcome was implantable cardioverter defibrillator discharge. We calculated relative risk [RR] for outcomes at 1-year follow-up for each study. We used the DerSimonian and Laird random-effects methods when there was significant heterogeneity between trials and the Mantel-Hanzel fixed-effects method when heterogeneity was negligible. RESULTS: We identified 3 trials of 1-2 years' duration. These trials included a total of 573 patients who received fish oil and 575 patients who received a control. Meta-analysis of data collected at 1 year showed no overall effect of fish oil on the relative risk of implantable cardioverter defibrillator discharge. There was significant heterogeneity between trials. The second largest study showed a significant benefit of fish oil (relative risk [RR] 0.74, 95% confidence interval [CI] 0.56-0.98). The smallest showed an adverse tendency at 1 year (RR 1.23, 95% CI 0.92-1.65) and significantly worse outcome at 2 years among patients with ventricular tachycardia at study entry (log rank p = 0.007). CONCLUSION: These data indicate that there is heterogeneity in the response of patients to fish-oil supplementation. Caution should be used when prescribing fish-oil supplementation for patients with ventricular tachycardia.
Subject(s)
Death , Defibrillators, Implantable , Dietary Supplements , Fish Oils/administration & dosage , Tachycardia, Ventricular/therapy , Adult , Aged , Female , Fish Oils/adverse effects , Follow-Up Studies , Humans , Male , Middle Aged , Myocardial Infarction/prevention & control , Primary Prevention/methods , Randomized Controlled Trials as Topic , Reference Values , Risk Assessment , Survival Rate , Tachycardia, Ventricular/diagnosis , Tachycardia, Ventricular/mortality , Treatment OutcomeABSTRACT
The Diet and Reinfarction Trial (DART) involved 2033 men (mean age 56.5 years) recovering from myocardial infarction. They were randomly allocated to receive advice or to receive no advice on each of three dietary factors: an increase in fatty fish intake; a reduction in fat intake with an increase in polyunsaturated fat:saturated fat; an increased intake of cereal fibre. Compliance was satisfactory with the fish and fibre advice, but less so with the fat advice. The men given fish advice had 29% lower 2-year all-cause mortality; the other forms of advice did not have any significant effects. The Diet and Angina Randomized Trial (DART-2) involved 3114 men (mean age 61.1 years) with stable angina, who were followed up for 3-9 years. Advice to eat oily fish or take fish oil did not affect all-cause mortality, but it was associated with a significant increase in sudden cardiac death (P=0.018), and this effect was largely confined to the subgroup given fish oil capsules. Advice to eat more fruit and vegetables had no effect, probably because of poor compliance. The outcome of DART-2 appears to conflict with that of DART and some other studies; various possible explanations are considered. Nutritional interventions are not equally acceptable and should be tailored to the individuals for whom they are intended. Various distinct groups have a raised risk of CHD, and it cannot be assumed that the same nutritional interventions are appropriate to them all. Nutritional supplements do not necessarily have the same effects as the foods from which they are derived.
Subject(s)
Dietary Fiber/administration & dosage , Fatty Acids, Unsaturated/administration & dosage , Fishes , Myocardial Infarction/diet therapy , Myocardial Infarction/prevention & control , Patient Compliance , Angina Pectoris/diet therapy , Angina Pectoris/mortality , Angina Pectoris/prevention & control , Animals , Dietary Supplements , Fish Oils/administration & dosage , Humans , Male , Middle Aged , Myocardial Infarction/mortality , Randomized Controlled Trials as Topic , Seafood , Secondary PreventionABSTRACT
BACKGROUND: Low folate status and elevated plasma homocysteine are associated with increased risk of neural tube defects and cardiovascular disease. Homocysteine responses to folate may be influenced by genetic variants in folate metabolism. OBJECTIVE: We determined the effect of folate-enhancing dietary interventions on plasma folate and plasma total homocysteine (tHcy) with respect to the methylenetetrahydrofolate reductase 677C-->T genotype. DESIGN: A total of 126 healthy subjects (42 TT, 42 CT, and 42 CC genotypes) completed 3 dietary interventions (4 mo each) in random order: 1) exclusion diet (avoidance of folic acid-fortified foods and ingestion of a placebo daily), 2) folate-rich diet (increased intake of fortified and naturally folate-rich foods to achieve 400 microg folate/d), and 3) supplement (exclusion diet plus a folate supplement of 400 microg/d). RESULTS: Plasma folate was higher (P < or = 0.001) and plasma tHcy lower (P < or = 0.001) after the folate-rich and supplement interventions than after the exclusion diet. Plasma folate was significantly greater after supplementation than after the folate-rich diet, but there was no significant difference in tHcy concentration (P = 0.72). TT homozygotes had higher plasma tHcy (14.5 compared with 8.9 micromol/L, P < or = 0.001) and lower plasma folate (14.8 compared with 19.0 nmol/L, P < or = 0.01) than did subjects with the CC genotype after the exclusion diet. CT heterozygotes had intermediate concentrations. The trend toward higher tHcy in TT homozygotes persisted throughout the study but was less marked with increasing folate intake (TT compared with CC after supplementation, P = 0.097). CONCLUSIONS: A folate-rich diet including folic acid-fortified foods or low-dose supplements effectively increases folate status. TT homozygotes require higher folate intakes than do individuals with the CT or CC genotype to achieve similar tHcy concentrations but are responsive to folate intervention.